Savara (NASDAQ:SVRA) Releases Earnings Results, Beats Estimates By $0.01 EPS

Savara (NASDAQ:SVRA) released its quarterly earnings data on Monday. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.01, reports.

Savara Stock Performance

NASDAQ:SVRA traded up $0.17 during mid-day trading on Wednesday, hitting $5.09. 4,986,666 shares of the company traded hands, compared to its average volume of 1,777,945. Savara has a one year low of $4.03 and a one year high of $7.01. The company has a quick ratio of 10.13, a current ratio of 10.13 and a debt-to-equity ratio of 0.21. The firm has a market cap of $1.05 billion, a price-to-earnings ratio of -8.80 and a beta of 0.32. The stock’s fifty day moving average price is $4.97 and its 200-day moving average price is $5.35.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. JPMorgan Chase & Co. started coverage on Savara in a report on Wednesday, October 7th. They set an “overweight” rating and a $12.00 target price on the stock. Wall Street Zen lowered shares of Savara from a “hold” rating to a “sell” rating in a report on Sunday, October 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a research report on Thursday, October 15th. Citigroup restated a “market outperform” rating on shares of Savara in a research note on Wednesday, October 7th. Finally, Royal Bank Of Canada set a $10.00 price objective on Savara in a research report on Wednesday, October 7th. Seven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.25.

Savara Company Profile

Savara is a biopharmaceutical company focused on developing treatments for serious and rare respiratory diseases. The company is based in the United States and concentrates its research and development efforts on conditions with limited treatment options. Savara’s lead product candidate is molgramostim, an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). It has been developed as a potential treatment for autoimmune pulmonary alveolar proteinosis, a rare lung disease in which the buildup of material in the air sacs can impair breathing.